These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 12062601)
1. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Kwok Y; DiBiase SJ; Amin PP; Naslund M; Sklar G; Jacobs SC Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):588-94. PubMed ID: 12062601 [TBL] [Abstract][Full Text] [Related]
2. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788 [TBL] [Abstract][Full Text] [Related]
3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
4. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379 [TBL] [Abstract][Full Text] [Related]
5. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244 [TBL] [Abstract][Full Text] [Related]
6. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy. Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584 [TBL] [Abstract][Full Text] [Related]
8. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358 [TBL] [Abstract][Full Text] [Related]
9. Isotope selection for patients undergoing prostate brachytherapy. Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561 [TBL] [Abstract][Full Text] [Related]
10. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Brachman DG; Thomas T; Hilbe J; Beyer DC Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979 [TBL] [Abstract][Full Text] [Related]
11. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related]
12. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671 [TBL] [Abstract][Full Text] [Related]
13. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410 [TBL] [Abstract][Full Text] [Related]
14. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558 [TBL] [Abstract][Full Text] [Related]
15. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Ko EC; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944 [TBL] [Abstract][Full Text] [Related]